New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

32

New TNBC Data for Merck’s Blockbuster Keytruda

Merck announced positive results from the late-stage KEYNOTE-522 study for Keytruda as a neoadjuvant treatment for triple negative breast cancer, which should support the company’s previous attempt for U.S. approval that was stymied by a regulatory advisory committee in February and rejected by the Food and Drug Administration in March.

35

FDA Approves Heron’s Zynrelef for Management of Postoperative Pain for up to 72 Hours

The U.S. Food and Drug Administration approved Heron Therapeutics Inc.’s Zynrelef (bupivacaine and meloxicam) extended-release solution for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty. 

37

CDC panel clears way to Covid-19 vaccines for U.S. adolescents

U.S. states are set to begin using the vaccine from Pfizer Inc. and BioNTech SE to inoculate young adolescents against Covid-19 after advisers to the U.S. Centers for Disease Control and Prevention (CDC) backed the plan in a unanimous vote on May 12.

40

GTO GROUP ANNOUNCES NEW WEBSITE LAUNCH

Greater Than One (GTO) Group, a privately held, full-service global health and wellness marketing and communications agency network focused on providing clients with a unique framework of custom practice offerings, announced the launch of its newly designed website at https:///www.thegtogroup.com/. The new site features easy access to essential information on GTO Group’s unique offerings of GTO full-service agency, GTO Media, and GTO Enterprise.